Skip Label
This website has been developed by Boehringer Ingelheim for people prescribed OFEV® (nintedanib) for Idiopathic Pulmonary Fibrosis (IPF) and Other Chronic Progressive Fibrosing Interstitial Lung diseases (ILD). These conditions are referred to collectively as "progressive pulmonary fibrosis (PPF)" on this website.
Side effects reporting can be found at the bottom of the page.
Exercise Area

Contact

Landscape image of Boehringer Ingelheim office

Please use the below details to get into contact with us.

Email

medinfo@bra.boehringer-ingelheim.com

Address

Boehringer Ingelheim Limited
Ellesfield Avenue
Bracknell
Berkshire
RG12 8YS
United Kingdom

Tel: +44(0)1344 742579
Fax: +44(0)1344 741444

NP-GB-103027 | July 2024

Access your progressive pulmonary fibrosis

Pulmonary fibrosis (PPF) support space

Access your progressive pulmonary fibrosis (PPF) support space

You have been directed here by your medical team because you have been prescribed OFEV® (nintedanib).

Please provide the password given to you by your medical team to access this space:

If you are unsure of your password, please contact the medical team that prescribed you OFEV® for more information.

Required.

THE INFORMATION ON THE FOLLOWING WEB PAGES IS SUITABLE AND ONLY INTENDED FOR PEOPLE LIVING IN THE UK AND IRELAND WHO HAVE BEEN PRESCRIBED OFEV®.

BY INPUTTING THE PASSWORD, YOU ARE CONFIRMING THAT YOU ARE A PATIENT PRESCRIBED THIS MEDICINE.

If you live in the UK and you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the yellow card scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.

If you live in the Republic of Ireland and you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Health Products Regulatory Authority at www.hpra.ie or by email to medsafety@hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.

THIS WEBSITE HAS BEEN DEVELOPED BY BOEHRINGER INGELHEIM AND IS INTENDED FOR PEOPLE WITH PROGRESSIVE PULMONARY FIBROSIS WHO HAVE BEEN PRESCRIBED OFEV® (NINTEDANIB).

This website is intended for people with progressive pulmonary fibrosis who have been prescribed treatment with OFEV® (nintedanib). OFEV® is used to treat idiopathic pulmonary fibrosis (IPF), or other chronic fibrosing interstitial lung diseases (ILDs) that are showing signs of progression and these diseases are referred to on this website collectively as ‘progressive pulmonary fibrosis’ (PPF).

This website aims to provide you with information about your disease and how to manage your symptoms or the side effects of your treatment, as well as to give you details on holistic support available.

The information on this website has been developed to enhance, but not replace, the advice and help of your medical team. If you have any questions after reading this website, or any further concerns, always talk to your medical team – i.e., a nurse, doctor or pharmacist – they are here to help you. 

You’ll also find more information about OFEV® in your Patient Information Leaflet (PIL), included with your OFEV® medication pack, or on https://www.medicines.org.uk/emc/files/pil.7705.pdf if you live in Great Britain, or on https://www.emcmedicines.com/en-gb/northernireland/medicine?id=1c9c7bb7-cac4-4c5f-a633-a8220c0a16dd&type=pil if you live in Northern Ireland or on https://www.medicines.ie/medicines/ofev-150-mg-soft-capsules-33198/patient-info if you live in the Republic of Ireland.

PPF support space

pulmonary fibrosis support space

Access your progressive pulmonary fibrosis (PPF) support space

This website is intended for people with progressive pulmonary fibrosis who have been prescribed treatment with OFEV® (nintedanib). OFEV® is used to treat idiopathic pulmonary fibrosis (IPF), or other chronic fibrosing interstitial lung diseases (ILDs) that are showing signs of progression and these diseases are referred to on this website collectively as “progressive pulmonary fibrosis” (PPF).  

This website aims to provide you with information about your disease and how to manage your symptoms or the side effects of your treatment, as well as to give you details on holistic support available. 

The information on this website has been developed to enhance, but not replace, the advice and help of your medical team. If you have any questions after reading this website, or any further concerns, always talk to your medical team i.e., a nurse, doctor or pharmacist – they are here to help you. 

You’ll also find more information about OFEV® in your Patient Information Leaflet (PIL), included with your OFEV® medication pack, or on https://www.medicines.org.uk/emc/files/pil.7705.pdf if you live in Great Britain, or on https://www.emcmedicines.com/en-gb/northernireland/medicine?id=1c9c7bb7-cac4-4c5f-a633-a8220c0a16dd&type=pil if you live in Northern Ireland or on https://www.medicines.ie/medicines/ofev-150-mg-soft-capsules-33198/patient-info if you live in the Republic of Ireland.

If you live in the UK and you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the yellow card scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.

If you live in the Republic of Ireland and you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Health Products Regulatory Authority at www.hpra.ie or by email to medsafety@hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.

THIS WEBSITE HAS BEEN DEVELOPED BY BOEHRINGER INGELHEIM AND IS INTENDED FOR PEOPLE WITH PROGRESSIVE PULMONARY FIBROSIS WHO HAVE BEEN PRESCRIBED OFEV® (NINTEDANIB).

This website is intended for people with progressive pulmonary fibrosis who have been prescribed treatment with OFEV® (nintedanib). OFEV® is used to treat idiopathic pulmonary fibrosis (IPF), or other chronic fibrosing interstitial lung diseases (ILDs) that are showing signs of progression and these diseases are referred to on this website collectively as ‘progressive pulmonary fibrosis’ (PPF).

This website aims to provide you with information about your disease and how to manage your symptoms or the side effects of your treatment, as well as to give you details on holistic support available.

The information on this website has been developed to enhance, but not replace, the advice and help of your medical team. If you have any questions after reading this website, or any further concerns, always talk to your medical team – i.e., a nurse, doctor or pharmacist – they are here to help you. 

You’ll also find more information about OFEV® in your Patient Information Leaflet (PIL), included with your OFEV® medication pack, or on https://www.medicines.org.uk/emc/files/pil.7705.pdf if you live in Great Britain, or on https://www.emcmedicines.com/en-gb/northernireland/medicine?id=1c9c7bb7-cac4-4c5f-a633-a8220c0a16dd&type=pil if you live in Northern Ireland or on https://www.medicines.ie/medicines/ofev-150-mg-soft-capsules-33198/patient-info if you live in the Republic of Ireland.


NP-GB-103027 | July 2024